Pressmediaofindia
Related Articles
25-03-2023
Bureau Report + Agencies
NEW DELHI/ TASHKENT: India has cancelled the manufacturing licence of a firm whose cough syrups been linked to 18 child deaths in Uzbekistan.
The WHO in January had warned against the use of two cough syrups made by Marion Biotech, saying they were substandard.
Marion Biotech denies the allegations.
After the deaths were reported in Uzbekistan, India’s health ministry had suspended production at the company.
On Wednesday, authorities in Uttar Pradesh state – where Marion Biotech is based – said they were now “permanently” cancelling the company’s licence.
“The firm based in Noida city cannot carry out any manufacturing now,” drug inspector Vaibhav Babbar told the Hindustan Times newspaper.
The media has reached out to state authorities for a statement.
Marion Biotech has not responded to media’s request for comment.
India is the world’s largest exporter of generic drugs, meeting much of the medical needs of developing countries but in recent months, many Indian firms have come under scrutiny for the quality of their drugs, with experts raising concerns about the manufacturing practices used to make these medicines.
The latest action against Marion Biotech came after tests by a government laboratory in December found 22 drug samples of the firm’s cough syrup to be “adulterated and spurious”.
“The adulterated and spurious drugs can cause grievous hurt to the public and it is suspected that related material/records may be disposed of,” Asheesh Kaundal, inspector of India’s Central Drugs Standard Control Organization (CDSCO), had said in his complaint.
Earlier this month, the Uttar Pradesh police had also arrested three employees of the company for selling adulterated products.
On Wednesday, SK Chaurasia, the Drugs Licensing Officer of Uttar Pradesh, said that Marion Biotech had failed to respond to the notice issued to them in connection with the findings “satisfactorily”.
India launched an investigation against Marion Biotech after the WHO issued a global medical alert, linking the deaths of 18 children in Uzbekistan to the firm’s Dok-1 Max and Ambronol cough syrups.
